SSA
MRTX

Schonfeld Strategic Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,161
Closed -$68.2K – 2533
2023
Q4 		$68.2K Sell
1,161
-29,539
-96% -$1.66M ﹤0.01% 1650
2023
Q3 		$1.34M Sell
30,700
-98,936
-76% -$3.53M 0.01% 928
2023
Q2 		$4.68M Buy
129,636
+106,837
+469% +$4.4M 0.04% 506
2023
Q1 		$848K Buy
22,799
+14,599
+178% +$657K 0.01% 1013
2022
Q4 		$372K Sell
8,200
-15,227
-65% -$985K ﹤0.01% 1692
2022
Q3 		$1.64M Sell
23,427
-8,574
-27% -$634K 0.01% 971
2022
Q2 		$2.15M Buy
+32,001
New +$2.04M 0.02% 726
2022
Q1 		– Sell
-16,350
Closed -$2.4M – 3029
2021
Q4 		$2.4M Sell
16,350
-2,377
-13% -$369K 0.02% 659
2021
Q3 		$3.31M Sell
18,727
-11,395
-38% -$1.83M 0.03% 547
2021
Q2 		$4.87M Buy
+30,122
New +$4.84M 0.05% 471
2021
Q1 		– Sell
-1,692
Closed -$373K – 2205
2020
Q4 		$373K Sell
1,692
-94
-5% -$20.3K 0.01% 1130
2020
Q3 		$297K Sell
1,786
-3,793
-68% -$519K 0.01% 1097
2020
Q2 		$637K Sell
5,579
-11,076
-67% -$1.07M 0.02% 727
2020
Q1 		$1.28M Sell
16,655
-11,482
-41% -$1.03M 0.08% 296
2019
Q4 		$3.63M Sell
28,137
-96,863
-77% -$9.34M 0.09% 250
2019
Q3 		$9.74M Sell
125,000
-95,400
-43% -$8.95M 0.29% 101
2019
Q2 		$22.7M Buy
220,400
+59,200
+37% +$4.61M 0.8% 16
2019
Q1 		$11.8M Buy
161,200
+70,300
+77% +$4.78M 0.41% 54
2018
Q4 		$3.86M Buy
90,900
+36,400
+67% +$1.45M 0.15% 192
2018
Q3 		$2.57M Sell
54,500
-34,600
-39% -$1.93M 0.11% 241
2018
Q2 		$4.39M Buy
+89,100
New +$3.37M 0.24% 147
2018
Q1 		– Sell
-32,113
Closed -$586K – 1019
2017
Q4 		$586K Buy
+32,113
New +$498K 0.05% 427

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Schonfeld Strategic Advisors's MRTX Position: Q1 2024 in Review

Schonfeld Strategic Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,161 shares — an estimated $68.2K sold.

Schonfeld Strategic Advisors first reported a position in MRTX in Q4 2017 and held it in 22 quarters. The position peaked at $22.7M in Q2 2019. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Schonfeld Strategic Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,161 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $68.2K.
  • Schonfeld Strategic Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 22 quarters.
  • Schonfeld Strategic Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $22.7M in Q2 2019.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2024, filed 15 May 2024.